Rat­tle and hum: Roche, PTC post up­date on their SMA drug as a shak­en Bio­gen faces yet an­oth­er fran­chise buster

Right on the heels of No­var­tis’ lat­est da­ta on its SMA gene ther­a­py for spinal mus­cu­lar at­ro­phy, PTC and its part­ners at Roche/Genen­tech post­ed their own pos­i­tive take on the lat­est da­ta for their oral ri­val ris­diplam. And a shaky Bio­gen will have to take it in­to ac­count as well as they as­sess the fu­ture for their block­buster drug Spin­raza, which has led the way on treat­ing this dis­ease for more than 2 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.